APLP2 and chronic kidney disease: Consistent with this, muscle-specific deletion of Stat3 and inhibition of CCAAT/enhancer-binding protein gamma (C/EBP δ) expression countered the loss of muscle mass in CKD (Zhang et al., 2013).